SavedAdd your journal

Journals / Türkderm-Deri Hastalıkları ve Frengi Arşivi / 2015 / Cilt: 49 - Sayı: 4

Pentraxin 3 levels in psoriasis, their relationship with disease severity and the efficacy of narrow-band ultraviolet B therapy

Psoriasiste pentraxin 3 düzeyi: Hastalık şiddeti ile ilişkisi ve darband ultraviyole B tedavisinin etkisi

İlkin ZİNDANCI
Mukaddes KAVALA
Zafer TÜRKOĞLU
Tuba ZORLU
Şermin DURAN
Burçe Can KURU
Pages
263–265
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Plasma PTX 3 levels in the patient group were measured before and after therapy by sandwich enzyme-linked immunosorbent assay in patients with the diagnosis of psoriasis and were compared with that in the control group.Results: The mean plasma PTX3 level in the patient group (1.24±0.83) was statistically significantly increased compared to that in the control group (0.55±0.26) (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background and Design: Pentraxin 3 (PTX 3), an acute phase protein, plays an important role in activation of innate immunity and in the regulation of inflammatory reactions.
📊
Key Findings & Data:Thus, considering the importance of PTX 3 in immune and inflammatory responses, it has been suggested that PTX 3 may play a role in the pathogenesis of psoriasis.
💡
Conclusion & Impact:Plasma PTX 3 levels in the patient group were measured before and after therapy by sandwich enzyme-linked immunosorbent assay in patients with the diagnosis of psoriasis and were compared with that in the control group.Results: The mean plasma PTX3 level in the patient group (1.24±0.83) was statistically significantly increased compared to that in the control group (0.55±0.26) (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background and Design: Pentraxin 3 (PTX 3), an acute phase protein, plays an important role in activation of innate immunity and in the regulation of inflammatory reactions. Thus, considering the importance of PTX 3 in immune and inflammatory responses, it has been suggested that PTX 3 may play a role in the pathogenesis of psoriasis. The aim of this study was to evaluate plasma PTX 3 levels in patients with psoriasis and their relationship with the disease severity and the effect of narrowband ultraviolet B (nbUVB) therapy on PTX 3 levels.Materials and Methods: The study comprised 40 patients with psoriasis and 88 age-and sex-matched healthy controls. Dermatological examinations and psoriasis area severity index (PASI) were performed. The patients received 20 courses of nbUVB therapy with a mean value of 13 joule/cm2. The efficacy of nbUVB was evaluated using PASI scores. Plasma PTX 3 levels in the patient group were measured before and after therapy by sandwich enzyme-linked immunosorbent assay in patients with the diagnosis of psoriasis and were compared with that in the control group.Results: The mean plasma PTX3 level in the patient group (1.24±0.83) was statistically significantly increased compared to that in the control group (0.55±0.26) (p

Özet

Amaç: Bir akut faz proteini olan pentraxin 3 (PTX 3) enflamatuvar cevabın düzenlenmesi ve doğal immunitenin aktivasyonunda önemli bir rol oynar. PTX 3'ün immun ve enflamatuvar cevaplara bu önemli etkisi nedeniyle psoriasisin patogenezinde rol oynayabileceği düşünülmüştür. Biz de çalışmamızda psoriasisli hastalarda plazma PTX 3 düzeyini, hastalık ile ilişkisini ve darband ultraviyole B (dbUVB) tedavisinin PTX 3 düzeyine etkisinin araştırdık.Gereç ve Yöntem: Çalışmaya 40 psoriasisli hasta ile yaş ve cinsiyet uyumlu 88 sağlıklı kontrol grubu dahil edildi. Hastaların dermatolojik muayeneleri yapıldı, psoriasis alan ve şiddet indeksi (PAŞİ) hesaplandı. Hastalara ortalama 13 joule/cm2, 20 seans dbUVB tedavisi uygulandı. Psoriasis vulgarisli hastaların tedavi öncesi ve tedavi sonrası PAŞİ ve plazma PTX 3 değerleri ile kontrol grubunun plazma PTX 3 düzeyleri ölçüldü. PTX 3 ölçümü için sandwich enzyme-linked immunosorbent assay yöntemi kullanıldı ve istatistiksel olarak karşılaştırıldı.Bulgular: Plazma PTX 3 düzeyleri psoriasisli hastalarda (1,24±0,83) kontrol grubuna (0,55±0,26) göre anlamlı derecede yüksek saptandı (p

🔖

Cite This Article

ZİNDANCI, İ., KAVALA, M., TÜRKOĞLU, Z., ZORLU, T., DURAN, Ş., KURU, B. C. (2022). Pentraxin 3 levels in psoriasis, their relationship with disease severity and the efficacy of narrow-band ultraviolet B therapy. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 49 - Sayı: 4, 263–265. https://ajindex.com/articles/621800

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Bachalez H: Immunopathogenesis of psoriasis:recent insights on the role of adaptive andinnate immunity. J Autoimmun 2005;25:69-73.
  2. Yoshinaga Y, Higaki M, Terajima S, et al: Detection of inflammatory cytokine in psoriatic skin. Arch Dermatol Res 1995;287:158-64.
  3. Bonifati C, Carducci M, Cordiali Fei P, Trento E, Sacerdoti G, Fazio M, Ameglio F, et al: Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients--relationships with disease severity. Clin Exp Dermatol 1994;19:383-7.
  4. Mantovani A, Garlanda C, Bottazzi B. Pentraxin 3: a nonredundant soluble pattern recognition receptor involved in innate immunity.Vaccine 2003;21:43-7.
  5. Bottazi B, Vouret-Craviari V, Bastone A, et al: Multimer formation and ligand recognition by the long pentraxin PTX 3-similarites and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem 1997;272:32817-23.
  6. Garlanda C, Bottazzi B, Bastone A, Mantovani A: Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005;23:337-66.
  7. Garlanda C, Hirsch E, Bozza S, Salustri A, De Acetis M, Nota R, et al: Non- redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 2002;420:182-6.
  8. Mantovani A, Garlanda C, Doni A: Pentraxins in innate immunity: From C-reactive protein to the long pentraxin PTX 3. J Clin Immunol 2008;28:1-13.
  9. Bevelacqua V, Libra M, Mazzarino MC, et al: Long pentraxin 3:a marker of inflammation in untreated psoriatic patients. Int J Mol Med 2006;18:415-23.
  10. Ctirad A, Lenka B, David P, et al: Goeckerman's therapy for psoriasis with special reference to serum pentraxin 3 level. Int J Dermatol 2008;47:1011-4.